Curemark CEO Dr. Joan Fallon To Be Featured Speaker At Two Scientific Conferences

19 October, 2015

RYE, New York, October 19, 2015 — Curemark, a drug research and development company focused on the treatment of neurological diseases for unmet medical needs, announced today that CEO and Founder, Dr. Joan Fallon, will be speaking at the following upcoming scientific conferences:

The Cleveland Clinic’s 2015 Medical Innovation Summit, “Memory. Mood. Movement.” The October 25 – 28 conference will explore the latest advances in healthcare innovation with a special focus on new products and treatments for the brain and nervous system. Dr. Fallon will join a panel on October 27 to discuss the latest innovations in diagnosis and therapy for Autism. For more information, visit: Cleveland Clinic 2015 Medical Innovation Summit
The MicroRNAs & NonCoding Europe 2015 meeting at the University of Cambridge, UK. On November 2, Dr. Fallon will deliver the keynote address on the role of endogenous and exogenous amino acids in neurodegenerative diseases. For more information, visit: GeneExpressions Systems’ Micro RNAs & END Europe 2015 Symposia

About Curemark, LLC
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s disease. For additional information, please visit our website at http://www.curemark.com or follow @curemark on Twitter.